Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Patients’ characteristics of all patients with urothelial cancer and spinal bone metastases
| Patients’ characteristics | ||
|---|---|---|
| Age | ||
| Median | 70 years | |
| Range | 35-82 years | |
| n | % | |
| Gender | ||
| Female | 8 | 21.0% |
| Male | 30 | 79.0% |
| Karnofsky performance status | ||
| 40-60% | 12 | 31.6% |
| 70% | 17 | 44.7% |
| 80% | 9 | 23.7% |
| Histology | ||
| Urothelial carcinoma | 38 | 100% |
| Localization of metastases | ||
| Thoracic | 18 | 47.4% |
| Lumbar | 20 | 52.6% |
| Number of metastases | ||
| Single | 15 | 39.5% |
| Multiple | 23 | 60.5% |
| Distant extra-osseous metastases | ||
| Overall | 9 | 23.7% |
| Lungs | 6 | 15.8% |
| Liver | 5 | 13.2% |
| Brain | 2 | 5.3% |
| Surgical corset | ||
| Yes | 6 | 15.8% |
| No | 32 | 84.2% |
| Treatment indications | ||
| Instability | 7 | 18.4% |
| Neurological symptoms | 1 | 2.6% |
| Pain | 30 | 79.0% |
| Radiotherapy schedule | ||
| 10 x 3 Gy | 24 | 63.2% |
| 14 x 2.5 Gy | 3 | 7.9% |
| 20 x 2 Gy | 11 | 28.9% |
| Systemic therapy | ||
| Chemotherapy | 14 | 36.8% |
| Bisphosphonates | 4 | 10.5% |